Danaher Corporation’s (DHR - Free Report) dental subsidiary, Envista Holdings Corporation, declared that it has successfully closed the initial public offering (IPO) of its common shares, which was announced this June. Envista started trading on the NYSE from Sep 18, 2019.
On Sep 20, shares of Danaher increased 0.49%, closing the trading session at $146.47. Meanwhile, Envista’s share price grew 2.75% to $28.77. Notably, Envista’s shares have gained 2.93% since it started trading on the stock exchange.
Inside the Headlines
As noted, Envista’s offering size amounted to 30,783.2 thousand shares, consisting of 26,768 thousand shares sold to the public at $22.00 per share and 4,015.2 thousand shares bought by the underwriters (exercising fully the option vested on them). The purchase price for the underwriters (after adjusting for underwriting discounts) was less than $22.00 for each share.
Net proceeds (after deduction of commissions and underwriting discounts) were $643.4 million. Envista has awarded the net proceeds to Danaher as part payment for the transfer of its dental assets.
Currently, Danaher holds approximately 80.6% shares in Envista.
Envista consists of Danaher Dental segment's three operating businesses — Nobel Biocare Systems, Ormco and KaVo Kerr. These businesses specialize in dental equipment, orthodontics, dental implants and consumables. Some notable brands are Nobel Biocare, Kerr, i-CAT, KaVo, Dexis, Pelton & Crane, Metrex, Ormco, Implant Direct, and Orascoptic.
Envista provides services to dentists (more than one million) across as many as 150 countries. It employs 12,000 people.
Zacks Rank, Earnings Estimates and Price Performance
With a market capitalization of approximately $105.1 billion, Danaher currently carries a Zacks Rank #2 (Buy). Over the past 60 days, the Zacks Consensus Estimate for its 2019 earnings remained stable at $4.79, while increased 2.4% to $5.59 for 2020.
Danaher Corporation Price and Consensus